Diagnosis, Risk Stratification, And Management Of Pulmonary Hypertension Of Sickle Cell Disease
Risk stratification guides clinical decision making in SCD:
- Mortality risk can be accurately determined by noninvasive measurement of the TRV via Doppler echocardiography.
- Serum NT-pro-BNP measurement is a reasonable noninvasive alternative when Doppler echocardiography is either unavailable or cannot obtain adequate images.
Note: Measurements may be misleading in patients with renal insufficiency.
- Mortality risk can also be determined invasively by direct hemodynamic measurements via right heart catheterization (RHC).
may be consistent with pre- or postcapillary PH or have features of both.
Diagnosis, Risk Stratification, And Management Of Pulmonary Hypertension Of Sickle Cell Disease.
March 5, 2014
Last Updated Month/Year
November 28, 2022
Supplemental Implementation Tools
External Publication Status
Country of Publication
Target Provider Population
Hematologists, pulmonologists, cardiologists, pediatricians, and internists
Male, Female, Adolescent, Adult, Child, Older adult
Health Care Settings
Nurse, nurse practitioner, physician, physician assistant
D006976 - Hypertension, Pulmonary, D000755 - Anemia, Sickle Cell
sickle cell disease, pulmonary hypertension, SCD, PAH